Overview

A Pilot Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy Subjects

Status:
Completed
Trial end date:
2020-11-16
Target enrollment:
Participant gender:
Summary
The 2 × 2 crossover designed study is to evaluate the bioequivalence of two different amphotericin B liposome for injection after single IV infusion at the same dose in normal healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Treatments:
Amphotericin B
Liposomal amphotericin B